LLaminar Pharma
Laminar Pharma is a Spanish biopharmaceutical company that designs first-in-class drugs based on "melitherapy" / Membrane-Lipid Therapy, targeting cell membrane lipids rather than proteins or DNA. Founded in 2006 as an academic spin-off of the University of the Balearic Islands, it is developing LAM561 (idroxioleic acid) for glioblastoma, alongside programs in other cancers and Alzheimer's. It has raised more than €43M since inception (around €29M since 2021), largely through equity crowdfunding platforms, family offices and private investors rather than institutional VC, and has joined the Growth segment of Spain's Entorno Pre Mercado ahead of a possible listing. It is headquartered in Palma de Mallorca, with a Boston office.
Founders
Global models 2
I
DIn the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 6
Open as list →
O
C
FFunding rounds 6
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-11-13 | No stage disclosed | €5.9M |
Lead not disclosed
+3 more
|
| 2023-10-06 | No stage disclosed | approximately €8.8M |
Dentol Capital
+1 more
|
| 2022-12-14 | No stage disclosed | €2M | Lead not disclosed |
| 2021-11 | No stage disclosed | €1.88M | Lead not disclosed |
| 2020-11-24 | No stage disclosed | up to €1.5M | Lead not disclosed |
| 2019-10-02 | No stage disclosed | €2M | Lead not disclosed |